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Summary due to anesthesia. In susceptible people, a malignant
hyperthermia (MH) episode is triggered by exposure to
Malignant hyperthermia susceptibility (MHS) is charac-
commonly used volatile anesthetic agents such as halo-
terized by genetic heterogeneity. However, except for
thane or depolarizing muscle relaxants such as succinyl
the MHS1 locus, which corresponds to the skeletal mus-
choline. A fulminant MH crisis is characterized by any
cle ryanodine receptor (RYR1) and for which several
combination of hyperthermia, skeletal muscle rigidity,
mutations have been described, no direct molecular evi-
tachycardia or arythmia, respiratory and metabolic aci-
dence for a mutation in another gene has been reported
dosis, and rhabdomyolysis. Except for this susceptibility
so far. In this study we show that the CACNL1A3 gene
to triggering agents, MHS patients are not clinically dis-
encoding the a1-subunit of the human skeletal muscle
tinguishable from the general population. Presymptom-
dihydropyridine-sensitive L-type voltage-dependent cal-
atic assessment of MH risk is performed by use of the
cium channel (VDCC) represents a new MHS locus and
in vitro contracture test (IVCT). Protocols for this test
is responsible for the disease in a large French family.
have been standardized by the European Malignant Hy-
Linkage analysis performed with an intragenic polymor-
perthermia Group (1984) and the North American
phic microsatellite marker of the CACLN1A3 gene gen-
Study Group for Malignant Hyperthermia (Larach
erated a two-point LOD score of 4.38 at a recombinant
1989). These protocols discriminate individuals as MH
fraction of 0. Sequence analysis of the coding region of
susceptible (MHS), MH normal (MHN), and MH
the CACLN1A3 gene showed the presence of an Arg-
equivocal (MHE). The latter category comprises individ-
His substitution at residue 1086, resulting from the tran-
uals for whom the biopsy sample reacts positively to
sition of A for G3333, which segregates perfectly with
one, but not both, of the in vitro triggering agents, halo-
the MHS phenotype in the family. The mutation is local-
thane (MHEh) and caffeine (MHEc).
ized in a very different part of the a1-subunit of the
Physiological and biochemical studies indicate thathuman skeletal muscle VDCC, compared with pre-
MHS is due to a malfunction in the mechanisms regulat-viously reported mutations found in patients with hypo-
ing sarcoplasmic calcium-ion ﬂuxes (MacLennan andkalemic periodic paralysis, and these two diseases might
Phillips 1992). On the basis of linkage studies in Irishbe discussed in terms of allelic diseases. This report is
families, an MHS locus was localized on chromosomethe ﬁrst direct evidence that the skeletal muscle VDCC
19q12-13.2 (McCarthy et al. 1990). The gene for theis involved in MHS, and it suggests a direct interaction
human skeletal muscle ryanodine receptor (RYR1), abetween the skeletal muscle VDCC and the ryanodine
calcium-release channel of the sarcoplasmic reticulum,receptor in the skeletal muscle sarcoplasmic reticulum.
was mapped simultaneously to the same region and was
shown to be tightly linked to MHS in Canadian families
Introduction (MacLennan et al. 1990).
Biochemical and electrophysiological studies inMalignant hyperthermia susceptibility (MHS), a skeletal
swine and humans with MHS pointed to the ryanodinemuscle disorder mostly inherited as an autosomal domi-
receptor as a likely candidate for the molecular defectnant trait (Kalow 1987), is one the main causes of death
(MacLennan and Phillips 1992). Base changes in the
RYR1 gene, leading to amino acid substitutions in the
gene product, cosegregate with the MHS phenotypeReceived January 27, 1997; accepted for publication March 28,
in a subset of human pedigrees with MHS (Gillard et1997.
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1994a; Zhang et al. 1993). However, a signiﬁcant Patients and Methods
number of families have also been described in which Proband, Pedigree, and IVCT Results
no linkage exists between markers for the RYR1 re-
The proband, individual lII-12, 30 years of age, diedgion and MHS (Deufel et al. 1992; Iles et al. 1992;
from a fulminant MH crisis during anesthesia. PatientLevitt et al. 1992).
III-12 developed tachycardia, extra systoles, and hy-In the search for additional MHS genes, a region on
percapnia 30 min after injection of suxamethoniumchromosome 17q11-24 was proposed, on the basis of
and administration of isoﬂurane. After 90 min, hyper-linkage studies in North American and southern African
thermia (40C) was observed, and isoﬂurane waspedigrees. The gene for the adult muscle sodium channel
stopped immediately. However, despite administra-(SCN4A) was suggested as a candidate (Levitt et al. 1992;
tion of dantrolene, the patient died from cardiac ar-Olckers et al. 1992). However, no molecular evidence for
rest. The family was then investigated for MHS, andthis assumption is presently available. On the other hand,
18 members of the family were then diagnosed on thethe skeletal muscle dihydropyridine-sensitive L-type volt-
basis of IVCT; 10 were classiﬁed as MHS, 5 as MHN,age-dependent calcium channel (VDCC) has been consid-
and 3 as MHEh.ered as a candidate forMHS, since this voltage-dependent
No distinctive clinical symptoms or histological fea-channel is responsible for the regulation of calciummove-
tures evidencing a skeletal muscle disease were identiﬁedment in skeletal muscle (Bean 1984). Furthermore, it has
in this family. The IVCT was performed according tobeen shown that the skeletal muscle VDCC and the ryan-
the European standard protocol (European Malignantodine receptor form the triad at the level of the junction
Hyperthermia Group 1984), and in ﬁgure 1 the resultsbetween the T-tubule and the sarcoplasmic reticulum
are indicated below each tested individual.(Marty et al. 1994; Takekura et al. 1994).
Of the four genes encoding subunits of the skeletal DNA Analysis of Microsatellite Markers
muscle 1,4-dihydropyridine-sensitive VDCC, three— Genomic DNA was extracted from whole blood by
the a1-subunit (CACLN1A3) on chromosome 1q use of a rapid guanidine method (Jeanpierre 1987). Am-
(Gregg et al. 1993a), the b-subunit (CACNLB1), and pliﬁcation by PCR was performed according to standard
the g-subunit (CACNLG), the latter two of which are protocols using primers for the microsatellite-repeat
localized on chromosome 17q11.2-q24 (Gregg et al. markers speciﬁed in table 1. For the CACNL1A3.PCR1
1993b; Powers et al. 1993), in proximity of the SCN4A amplimer (GDB accession number 196341), PCR was
locus—have been excluded as candidates in German, performed in a 25-ml volume containing 0.4 pmol of
British, and Belgium pedigrees (Iles et al. 1993; Sudbrak forward primer 5 end-labeled with 32P, 200 mM
et al. 1993). However, cosegregation of MHS with dNTPs, and 0.25 U of Taq polymerase (Appligene). Am-
the marker D7S849 adjacent to the gene for the pliﬁcation was performed as described previously, ex-
a2/d-subunit of the dihydropyridine-sensitive VDCC cept that only 30 cycles were run and that annealing
(CACNL2A), which map to chromosome 7q21-22 temperature was 62C. After denaturation with for-
(Powers et al. 1994), was reported in one German pedi- mamide, 32P-5 end–labeled ampliﬁcation products
gree (Iles et al. 1994a). To our knowledge, no mutations were loaded onto a 6% polyacrylamide/8 M urea DNA
in this gene have been described to date. More recently, sequencing gel prior to autoradiography.
we initiated a European collaborative search for addi-
Data Analysistional MHS loci, using a panel of MHS pedigrees with
the MHS trait not linked to the RYR1 gene. A clear Linkage analysis was performed by use of the 5.2
LINKAGE package (Lathrop and Lalouel 1984). Thelinkage between the MHS phenotype and markers de-
ﬁning a 1-cM interval on chromosome 3q13.1 was de- pedigree ﬁles were created with the 1.1 Cyrillic program
(Cherwell Scientiﬁc Publishing). Parameters were set asscribed (Sudbrak et al. 1995). However, no candidate
genes have been identiﬁed in this region so far. deﬁned by the genetics section of the European Malig-
nant Hyperthermia Group and reported elsewhere (Sud-We report here an MHS pedigree in which the MHS
phenotype is genetically associated with the CACLN1A3 brak et al. 1995): the disease-allele frequency was 1/
10,000, the penetrance for the index case was taken asgene, which encodes the a1-subunit of the skeletal mus-
cle VDCC. This represents the ﬁrst characterization 1.0, and the penetrance of the disease heterozygote was
set at .98; the phenocopy rate was .02, and MHE indi-of a mutation responsible for MHS in a gene other
than RYR1. Interestingly enough, mutations of the viduals were assigned unknown status (i.e., they do not
contribute to the LOD score in this family). In the ab-CACNL1A3 that so far have been described have been
exclusively associated with hypokalemic periodic paral- sence of speciﬁc data, allele frequencies for the hyperva-
riable microsatellite markers were set as equal and thusysis (hypoKPP) (Jurkat-Rott et al. 1994; Ptacek et al.
1994). These results will be discussed in terms of patho- as dependent on the maximum number of alleles re-
ported for each marker.logical model and allelic diseases.
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Figure 1 Segregation, in the VE2GR pedigree, of the Arg1086His mutation with the MHS trait. Blackened symbols denote patients tested
with the IVCT and phenotyped as MHS; unblackened symbols denote those typed as MHN; hatched symbols denote those typed as MHEh;
and unblackened symbols with a question mark denote untested family members (i.e., disease status is unknown). The index patient (III-12),
marked by an arrow, died from a fulminant MH crisis. The presence or absence of the Arg1086His mutation is indicated by a plus sign (/)
or a minus sign (0), together with the result of genotyping for polymorphic marker CACNL1A3.PCR1. Results of IVCT are reported in boxes
below each tested individual. Values indicated (expressed in g) correspond to muscle-ﬁber contractures in the presence of either 2% halothane
(h) or 2 mM caffeine (c).
Analysis of Genomic DNA and cDNA primed cDNA was synthesized from 1 mg of total RNA
in a ﬁnal volume of 50 ml, by use of a ﬁrst-strand cDNABlood samples and muscle biopsy were obtained with
synthesis kit (Stratagene). Reverse transcription–PCRthe appropriate informed consent of the patients, in
was performed in a ﬁnal volume of 50 ml, by use of 1.5agreement with French ethical rules. Total RNA was
ml of the reaction as template, 1 mM primers, and 0.5extracted from a 100-mg vastus lateralis muscle-biopsy
U of Taq polymerase (Appligene). Ampliﬁcation param-sample of MHS patient III-14, as described elsewhere
eters were as follows: initial denaturation at 94C for 2(Chomczynski and Sacchi 1987). Random hexamer–
min; 35 cycles of 94C for 30s, 58C for 30 s, and 72C
for 1 min; and a ﬁnal extension at 72C for 10 min.
Twelve overlapping fragments were ampliﬁed—(153-
Table 1 795), (675-1235), (1188-1680), (1558-2176), (2054-
2605), (2558-3230), (3037-3692), (3448-4019), (3925-Two-Point LOD-Score Values for Linkage between MHS and
Markers from Potential Chromosomal Candidate Regions 4480), 4368–4925), (4752-5320), and (5257-6021).
Base assignment was done according to the cDNA de-
LOD Score at scribed by Hogan (Hogan et al. 1994) (Genbank acces-
Chromosome and Recombination
sion number 33798). Alternativately, exons were ampli-Microsatellite Marker Fraction 0 Reference
ﬁed from genomic DNA by use of exon-speciﬁc intronic
1q: primers (Hogan et al. 1996) (Genbank accession num-
CACLN1A3.PCR1 /4.38 Gregg et al. (1993a) bers U30666–U30707).
3q:
Direct Sequencing of PCR ProductsD3S1281 07.97
Subdrak et al. (1995)
D3S1616 07.96 PCR-ampliﬁed fragments obtained from cDNA or ge-
7q: nomic DNA were puriﬁed by use of the Qiaex DNA-
D7S660 01.6
puriﬁcation system (Diagen). In order to eliminate anyD7S849 03.01 Iles et al. (1994a)
sequence error resulting from polymerase activity, threeD7S254 04.92
17q: independently ampliﬁed products of each fragment were
D17S518 05.36 sequenced by use of an ABI 373 apparatus and the PCR
D17S250 05.44 Levitt et al. (1992) primers as sequencing primers.
NM23 05.46
19q: Mutation Analysis
D19S191 0.95 For extensive screening of the Arg1086His mutation,
D19S220 06.27
analysis of the GrA transition was alternatively per-
/ 9a2a$$ju03 05-21-97 19:29:02 ajhga UC-AJHG
1319Monnier et al.: MHS and DHP-Sensitive Calcium Channel
formed on genomic DNA by restriction digestion using the CACNL1A3 cDNA yielded 10 sequence changes (ta-
ble 2). All the sequence modiﬁcations were conﬁrmedHhaI. A 226-bp-long fragment encompassing the muta-
tion was ampliﬁed by use of the 25i5 forward primer, by analysis of the genomic DNA. Sequence changes lead-
ing to modiﬁcation of amino acids at positions 265, 574,5-CTTGGTGCTGACCTGTCCTGTT, and the 25i3
reverse primer, 5-GATCAGACATTTTTCTCCTGGGG. 627, 628, 918, 919, 1180, 1671, 1815, and 1840 are
present as homozygous changes. Except for modiﬁcationDigestion of the normal allele generates two fragments,
190 and 36 bp long, whereas the mutated allele is not of amino acids at positions 1815 and 1840, all substitu-
tions that we report lead to changes in amino acid com-cut. Digested fragments were analyzed on a 6% acryl-
amide gel. position that are strictly conserved in genes encoding
the dihydropyridine-sensitive VDCC from rabbit, rat,
carp, Drosophila, and human skeletal muscle (TanabeResults
et al. 1987; Grabner et al. 1991; Zheng et al. 1995;
MHS Phenotype in the VE2GR Family: Association Hogan et al. 1994). Therefore, it is likely that these
with the CACLN1A3 Gene on Chromosome 1q31 amino acid corrections correspond to the actual se-
quence and do not represent infrequent polymorphisms.Combined pairwise LOD scores with informative
On the other hand, two polymorphisms present at themarkers adjacent to previously identiﬁed MHS loci on
heterozygous level were also found. The ﬁrst corre-chromosomes 19q, 17q, 7q, and 3q are listed in table 1.
sponds to a A1598T substitution and results in aNegative LOD-score values obtained with the different
HisrLeu substitution at amino acid residue 458 (tablemarkers indicate exclusion of MHS from these loci in
3). This polymorphism corresponds to a sequence varia-the VE2GR family. Since (i) a well-documented MH
tion between exonic and cDNA sequences that has beencrisis had been observed in the index case, (ii) exclusion
described elsewhere (Gregg et al. 1993a). The second isof previously described MHS loci was established, and
a CrT substitution at position 4840 and results in an(iii) the pedigree was large enough to allow for an indi-
ArgrCys change at amino acid 1539. Since it has beenvidual LOD score ú3.0 with positive linkage, the
reported that ArgrCys mutations in the RYR1 gene areVE2GR pedigree was included in a systematic human-
associated with MHS (Gillard et al. 1991; Quane et al.genome linkage study using a panel of MHS families.
1994b), we critically checked the distribution of thisThis was part of a collaborative European project aimed
polymorphism in the VE2GR family. This C4840T sub-at the identiﬁcation of additional MHS loci. Preliminary
stitution was found in both MHN andMHS individuals,data obtained from this general search pointed to the
and its segregation clearly failed to follow the MHS1q31 region as a potential region for an MHS locus
phenotype. Therefore, this sequence modiﬁcation isin this family. The CACNL1A3 gene encoding the a1-
likely to represent a simple polymorphism.subunit of the skeletal muscle VDCC has been mapped
The ﬁnal DNA alteration detected was the substitu-to chromosome 1q31-32 (Gregg et al. 1993a) and
tion of an A for G3333 in the cDNA, resulting in aninternal polymorphic markers for this gene
Arg1086His mutation in the a1-subunit of the skeletal(CACNL1A3.PCR1 and CACNL1A3.PCR2) have been
muscle VDCC (ﬁg. 2). The mutation is localized at theidentiﬁed (Gregg et al. 1993a; Iles et al. 1994b). We
very beginning of exon 25 and abolishes a HhaI restric-tested these markers in the VE2GR family. Only the
tion site. Accordingly, we screened for the presence orCACNL1A3.PCR1 marker worked in our study and
the absence of this site, by constructing PCR primersproved to be fully informative in the family. A clear
in the ﬂanking introns, whose boundaries are located,segregation of allele 5 was obtained with the MHS phe-
respectively, 2 bp upstream of the mutation and 157 bpnotype (ﬁg. 1). Two-point LOD-score calculation be-
downstream of the mutation. PCR ampliﬁcation yieldedtween this marker and the MHS trait in this family gen-
a fragment of 226 bp, which, in the MHS family thaterated a LOD-score value of 4.38 at 0 cM, compared
we studied, was fully cleaved in normal individuals andwith the 4.46 maximum LOD-score value obtained in
was 50% cleaved in heterozygous individuals (ﬁg. 3).simulation studies using MSIM, a LINKAGE-based
This mutation replaces an amino acid that is strictlypackage.
conserved in brain and endocrine human VDCC iso-
Arg1086His Mutation in the CACLN1A3 Gene: forms and in all species in which the CACNL1A3 cDNA
Association with the MHS Phenotype has been sequenced so far (ﬁg. 4).
We found the Arg1086His mutation as a heterozy-We isolated the cDNA of the CACNL1A3 gene from
a skeletal muscle biopsy of MHS individual III-14. Alter- gous trait in 10 individuals of the family (II-4, II-6, II-
8, III-1, III-2, III-3, III-6, III-14, III-16, and III-18; ﬁg.natively, sequencing of genomic DNA was performed
on ampliﬁed exonic DNA. The CACNL1A3 cDNA was 1) who were diagnosed for MHS by use of IVCT. We
also found the mutation in two obligate carriers (II-2ampliﬁed by PCR, in overlapping products of Ç600 bp.
Direct sequencing of the PCR products obtained from and II-9) and in two MHEh individuals (III-5 and III-
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Table 2
Sequence Corrections in CACNL1A3 cDNA, and Predicted Amino Acid Sequence
AMINO ACID POSITION
SEQUENCE 265 505 574 627 628 918 919 1180 1671 1814 1815 1840
Original:a
Amino acid Cys Cys Arg Ser Ser Ala Arg Asn Ala Leu Gly Asp
cDNA TGC TGC CGC TCG AGC GCT AGG AAC GCG CTC GGA GAC
Corrected:b
cDNA TGG TGT GGC TAC GGC GTG CAG GAC CCG CTG GCA GAG
Amino acid Trp Cys Ala Tyr Gly Val Gln Asp Gly Leu Ala Glu
Amino acid:
Rabbitc Trp Cys Ala Tyr Gly Val Gln Asp Gly Leu Val Gln
Ratc Trp Cys Ala Tyr Gly Val Gln Asp Gly Leu Val Gln
Carpd Trp Cys Ala Tyr Gly Val Gln Asp Val Leu Val Ser
Drosophila e Trp Cys Ala Tyr Gly Val Gln Asp Gly Leu Arg Ser
a Hogan et al. (1994)
b Changes from original sequence are underlined.
c Tanabe et al. (1987).
d Grabner et al. (1991).
e Zheng et al. (1995).
11) who presented a strong response to halothane only. children (IV-1, IV-2, and IV-7) who had not yet been
subjected to the diagnostic test. The mutation was notThese two MHEh patients, whose status was based on
IVCT, were MHS patients on the basis of haplotyping found in 100 independent MHN chromosomes belong-
ing to nonrelated IVCT-negative patients from pedigreeswith the CACLN1A3.PCR1 marker and the Arg1086His
mutation as polymorphisms. The mutation was absent
from six members of the family diagnosed as MHN after
IVCT. The LOD score for linkage between the mutation
in CACNL1A3 and MHS was 4.38, at a recombination
fraction of 0. We extended the analysis to additional
members of the family and found the mutation in three
Table 3
Polymorphisms in CACNL1A3 Coding Sequence
AMINO ACID POSITION
SEQUENCE 458 1539
Original:a
Amino acid His Arg
cDNA CAC CGC
Found:
cDNA CAC/CTC CGC/TGC
Amino acid His/Leu Arg/Cys
Amino acid:
Rabbitb Leu Arg
Ratb Leu Arg
Carpc Glu Arg
Drosophilad Asp Arg
Figure 2 DNA sequencing of the cDNA of the CACNL1A3
gene. The ABI sequencing proﬁle shows a heterozygous GrA substitu-a Hogan et al. (1994).
b Tanabe et al. (1987). tion at position 3333 in MHS patients that is not observed in MHN
patients. The DNA sequence of the coding strand with the amino acidc Grabner et al. (1987).
d Zheng et al. (1995). translation is shown below the graph.
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fect—that a gene other than RYR1 is involved in MHS.
Therefore, our data represent the ﬁrst ironclad report
of locus heterogeneity for MHS.
Three individuals (IV-1, IV-2, and IV-7) too young to
have an IVCT carry the mutation. Identiﬁcation of the
CACNL1A3 gene mutation allows a direct genetic diag-
nosis for those patients in the VE2GR family who are
at risk for MHS. Among the three individuals who were
diagnosed as MHE by IVCT, two (III-5 and III-11) have
Figure 3 Screening of the GrA mutation at position 3333, by the mutation and can be considered MHS from a genetic
analysis of the presence or the absence of an HhaI restriction-endonu- point of view (i.e., on the basis of mutation and haplo-
clease site in the 226-bp PCR fragment from genomic DNA of individ- typing). The third MHE patient (II-7) does not have the
uals from a grouping within the pedigree described in ﬁgure 1. Cleav-
mutation and is unrelated to the ﬁrst generation of thisage of the 226-bp fragments generated 190- and 36-bp fragments.
MHS family. Despite the fact that the gene frequency forBecause of the gel composition used and the ethidium bromide visuali-
sation, the 36-bp fragment did not give a neat signal on gels; therefore, MHS is estimated at only 1/10,000, one cannot formally
only ethidium bromide ﬂuorescent signals corresponding to the uncut exclude the presence of another MHS-associated muta-
226-bp fragment and to the 190-bp fragment generated after HhaI tion in this individual, which might explain the partial
digestion are shown in the ﬁgure. All MHS patients and the MHE
response to halothane. Conversely, in some of ourpatient are heterozygous for the G3333A mutation; and all MHN
study’s MHS families in which the disease has beenpatients are homozygous for the normal sequence. Symbols and num-
bering are as deﬁned in ﬁgure 1. clearly associated with a mutation in the RYR1 gene,
we have observed that individuals can test as MHEh or
MHEc even in the absence of the causative mutation
(data not shown).at risk for MHS. The mutation was also absent in a
IVCT results obtained in this family in which MHSpopulation of 50 unrelated MHS individuals belonging
is associated with the Arg1086His mutation in the a1-to MHS families mostly linked to the RYR1 locus.
subunit of the skeletal muscle VDCC did not differ sig-
niﬁcantly from those obtained in families in which MHSDiscussion
is associated with an RYR1 mutation. Interestingly,
skeletal muscle VDCC mutations might cause hypoKPPThis report represents the ﬁrst genetic evidence of a
mutation affecting a voltage-dependent calcium channel (MIM 170400; McKusick 1990), and three different
mutations of the CACNL1A3 gene have been associatedof the skeletal muscle and associated with MHS. Results
obtained in a French MHS pedigree with the MHS trait with the disease (Jurkat-Rott et al. 1994; Ptacek et al.
1994). HypoKPP belongs to a particular group of skele-deﬁned according to the European IVCT protocol pro-
vide direct evidence that MHS is associated with an tal muscle diseases that are due to an abnormal function
of ion channels: the ‘‘muscle ion-channel diseases.’’ ThisArg1086His mutation in the product of the CACNL1A3
gene on chromosome 1q31. The Arg1086His mutation disorder is transmitted as an autosomal dominant trait
and is characterized by episodic weakness associatedin CACNL1A3 appears to be a private mutation, re-
stricted so far to a single French pedigree among ú50 with decreased serum potassium concentration. Thus,
defects in CACLN1A3 can lead to various symptomsFrench and Italian MHS families that we have tested.
This situation is not unusual, since it was also the case and to various disease nomenclatures. On the basis of
these studies, at least some forms of MHS and hypoKPPfor some RYR1 mutations (Zhang et al. 1993; Quane
et al. 1994b) and for the reports linking MHS with other
loci (Iles et al. 1994a; Sudbrak et al. 1995). Together
with the clear segregation of the mutation with the MHS
trait and the fact that the mutation affects a well-con-
served amino acid, the absence of the mutation in 100
unrelated MHN chromosomes contributes to exclude
this mutation as being a simple polymorphism. MHS is
characterized by both allelic and genetic heterogeneities.
As a matter of fact, ú10 different mutations of the
Figure 4 Amino acid sequence of the a1-subunits and relatedRYR1 gene have been reported, illustrating a clear-cut
isoforms in the region ﬂanking the residue Arg1086. This region corre-allelic heterogeneity in RYR1. On the other hand, at
sponds to the cytoplasmic domain of the dihydropyridine receptor,
least four different loci have been associated with MHS. localized between the S6 transmembranous sequence of domain III
However, none of them has offered direct proof—that and the S1 transmembrane segment of domain IV (Hogan et al. 1994).
Residues identical to the human sequence are indicated by dots.is, a two-point LOD score ú/3.0 or a molecular de-
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appear to be allelic disorders. A similar situation exists are thought to function as voltage sensors (Catterall
1988). Since the EC coupling and calcium-conductingwith hypoKPP and paramyotonia congenita, both of
which result from mutations in the adult sodium-chan- properties of the dihydropyridine-sensitive VDCC are
voltage sensitive, it was postulated that these mutations,nel gene SCN4A (Ptacek et al. 1993), and with MHS
and CCD. In the latter situation, both pathologies are which involve the loss of an arginine, a positively
charged amino acid, in the S4 segments may alter onecaused by mutations in the RYR1 gene (Quane et al.
1993; Zhang et al. 1993), with some mutations being or both of these functions. On the other hand, on the
basis of studies of chimeric dihydropyridine receptors,associated with both phenotypes in some patients
whereas other mutations are associated speciﬁcally with it has been shown that the putative cytoplasmic region
between domains II and III of the a1-subunit of theMHS. However, in contrast to the situation with MHS
and CCD, a study investigating the relation of MHS skeletal muscle VDCC is an important determinant of
skeletal-type excitation-contraction (EC) coupling (Ta-with hypoKPP indicated that the latter is not associated
with MHS (Lehmann-Horn and Iaizzo 1990). In agree- nabe et al. 1990), whereas the cytoplasmic region be-
tween domains I and II might be involved in interactionsment with that report, no clinical symptoms or biologi-
cal signs that might be associated with hypoKPP have with the b-subunit of the skeletal muscle VDCC (Prag-
nell et al. 1994). The a1-subunit domain I-II linker con-been observed in the VE2GR family. However, in the
literature a case has been reported in which a patient tributes also to a PKC-dependent up-regulation of the
channel activity, through a direct interaction with a G-with hypoKPP experienced an MH episode. This patient
was the only case of hypoKPP in his family and was protein bg complex (De Waard et al. 1997; Zamponi et
al. 1997). The a1-subunit of the skeletal muscle VDCCclassiﬁed asMHEh after IVCTwas performed on a mus-
cle biopsy (Lambert et al. 1994). is an in vivo substrate for many protein kinases, and
several phosphorylation sites have been characterizedThe hypoKPP mutations that so far have been de-
scribed occur in the S4 segments of domains II within the COOH terminal region of the protein (De
Jongh et al. 1989). It is interesting, however, to note(Arg528His) and IV (Arg1239His and Arg1239Gly) (ﬁg.
5). The S4 segments of these voltage-gated ion channels that two isoforms of the a1-subunit have been described
Figure 5 Schematic representation of the a1-subunit of the skeletal muscle dihydropyridine receptor. Sequences involved in both EC
coupling and interaction with the b-subunit of the dihydropyridine receptor are shown in boldface. S4 transmembrane segments of the different
domains that operate as voltage sensors are blackened, and dihydropyridine binding sites and phosphorylation sites present in the C-terminal
region are indicated. Positions of the sequence modiﬁcations are represented: black dots denote homozygous corrections; black triangles denote
heterozygous polymorphisms; and black diamonds denote Arg1086His mutation.
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in adult skeletal muscle. The minor, full-length form phies and the dystophin-associated proteins in the skele-
tal muscle (Sunada and Campbell 1995). In the lattercontains 1,873 amino acids, whereas the major form,
truncated in the COOH terminal region, is 1,685 amino case, almost identical clinical phenotypes are associated
with defects of genes encoding functionally associatedacids long (De Jongh et al. 1991). Three dihydropyridine
binding sites have been described between the S5 and proteins. Expression studies of the mutated subunit and
biochemical investigations will provide more insight intoS6 transmembrane segments of domains I, III, and IV
(Kalasz et al. 1993). the interactions between the skeletal muscle VDCC and
the RYR receptor in the regulation of calcium move-Except on exposure to halogenated anesthetics and
succinyl choline, most MHS individuals do not usually ments in skeletal muscle ﬁbers.
present symptoms related to the muscle ion-channel dis-
eases. This suggests that a mutation associated with the
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